$HELP

Halstead Michael purchased $1.3M of HELP

Halstead Michael (Chief Executive Officer) purchased 100,000 shares of CYBIN INC. (HELP) at $13.47 ($1.35M total) on 2026-09-21.

Original reporting
SEC EDGAR · Halstead Michael
Published Sep 21, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
medium confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishLow
01

Why it matters

The purchase adds to CEO's ownership, possibly indicating confidence in upcoming developments.

02

Market read

Insider purchase may modestly influence HELP's stock price; relevance limited to traders tracking insider activity.

03

What to watch

Potential upcoming clinical trial data or regulatory news not disclosed.

Relevance 7/10Novelty 6/10Timing: today

Background

Form 4 filing reports insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$HELPBullishMedium confidence
Context

CEO Halstead Michael bought 100,000 shares of Cybin Inc. for $1.35M, increasing his stake to 168,568 shares.

Expected impact

Potential slight upward pressure in near term.

Evidence & confidence

CEO acquisition of $1.3M worth of stock is a primary disclosure but modest in scale; traders may view as a mild bullish cue.

Market effects

Limited impact on biotech sector; reflects insider confidence.

Minimal regional effect.

Low global relevance.

Counterpoint

Insider buying could be routine portfolio rebalancing, not a strong signal.

Key entities

  • Cybin Inc.

    Biopharmaceutical company developing psychedelic therapeutics.

  • Halstead Michael

    Chief Executive Officer of Cybin Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Helus Pharma (HELP) shares rose to a 52-week high of $15.15 before falling 11% after Barclays initiated coverage with an Overweight rating and $35 price target. The company awaits Q4 trial results for its psychedelic drug HLP003, with FDA Breakthrough Therapy status. Analysts' average price target is $41.40, implying 195% upside. HELP has gained 53% year-to-date.